Fas (Fas cell surface death receptor) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Fas (Fas cell surface death receptor) Rattus norvegicus
Symbol: Fas
Name: Fas cell surface death receptor
RGD ID: 619831
Description: Enables protease binding activity and tumor necrosis factor receptor activity. Involved in several processes, including cellular response to cobalt ion; cellular response to cytokine stimulus; and nervous system development. Located in several cellular components, including apical dendrite; external side of plasma membrane; and sarcolemma. Part of CD95 death-inducing signaling complex. Used to study IgA glomerulonephritis; brain glioma; pre-malignant neoplasm; retinal detachment; and transient cerebral ischemia. Biomarker of several diseases, including abdominal obesity-metabolic syndrome 1; artery disease (multiple); brain ischemia (multiple); eye disease (multiple); and liver disease (multiple). Human ortholog(s) of this gene implicated in several diseases, including autoimmune disease (multiple); cystic fibrosis; hematologic cancer (multiple); pre-eclampsia (multiple); and urinary system cancer (multiple). Orthologous to human FAS (Fas cell surface death receptor); PARTICIPATES IN extrinsic apoptotic pathway; FasL mediated signaling pathway; intrinsic apoptotic pathway; INTERACTS WITH (S)-nicotine; 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,2-dimethylhydrazine.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: apo-1 antigen; apoptosis-mediating surface antigen FAS; CD95 antigen; Fas (TNF receptor superfamily, member 6); Fas antigen (ATP1); Fas receptor; FASLG receptor; FasR; Tnfrsf6; tumor necrosis factor receptor superfamily member 6; Tumor necrosis factor receptor superfamily, member 6
RGD Orthologs
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21231,798,963 - 231,832,591 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1231,798,960 - 231,832,591 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1240,190,049 - 240,223,613 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01247,111,767 - 247,145,407 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01239,949,944 - 239,983,507 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01252,589,785 - 252,624,790 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1252,589,785 - 252,624,790 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01259,812,248 - 259,846,107 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41238,259,443 - 238,274,745 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11238,423,465 - 238,438,767 (+)NCBI
Celera1228,912,823 - 228,946,152 (+)NCBICelera
Cytogenetic Map1q52NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
abdominal obesity-metabolic syndrome 1  (IEP)
Acute Experimental Pancreatitis  (ISO)
acute kidney failure  (ISO)
Acute Liver Failure  (ISO)
Acute Lung Injury  (ISO)
acute lymphoblastic leukemia  (ISO)
acute myeloid leukemia  (ISO)
adult T-cell leukemia/lymphoma  (ISO)
alcoholic hepatitis  (IEP)
Alcoholic Liver Diseases  (ISO)
Alzheimer's disease  (ISO)
Animal Disease Models  (ISO)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis  (ISO)
aplastic anemia  (ISO)
asthma  (IEP)
atherosclerosis  (IEP,ISO)
autoimmune disease  (ISO)
autoimmune hepatitis  (ISO)
autoimmune lymphoproliferative syndrome  (ISO,ISS)
Autoimmune Lymphoproliferative Syndrome, Type IA  (ISO)
autoimmune thrombocytopenic purpura  (ISO)
B-Cell Chronic Lymphocytic Leukemia  (ISO)
Barrett's esophagus  (ISO)
Behcet's disease  (ISO)
brain glioma  (IDA)
Brain Hypoxia-Ischemia  (IEP)
Brain Injuries  (IEP,ISO)
brain ischemia  (IEP)
breast cancer  (ISO)
breast carcinoma  (ISO)
cardiomyopathy  (ISO)
Cardiotoxicity  (ISO)
Cardiovascular Pregnancy Complications  (ISO)
cataract  (ISO)
Chemical and Drug Induced Liver Injury  (IEP)
Chest Trauma  (IEP)
chorioamnionitis  (ISO)
chronic conjunctivitis  (ISO)
chronic myeloid leukemia  (ISO)
chronic obstructive pulmonary disease  (IEP)
Chronic Uveitis  (ISO)
clonorchiasis  (IEP)
Colonic Neoplasms  (IEP)
congestive heart failure  (IEP,ISO)
corneal neovascularization  (ISO)
cryptorchidism  (IEP)
cystic fibrosis  (ISO)
dermatomyositis  (ISO)
diabetic angiopathy  (ISO)
Diabetic Nephropathies  (IEP,ISO)
diffuse large B-cell lymphoma  (ISO)
dilated cardiomyopathy  (IEP,ISO)
Disease Progression  (ISO)
endophthalmitis  (IEP)
Endotoxemia  (IEP)
Esophageal Neoplasms  (ISO)
esophagus adenocarcinoma  (ISO)
Experimental Allergic Asthma  (IEP)
Experimental Autoimmune Uveitis  (ISO)
Experimental Colitis  (IDA)
Experimental Diabetes Mellitus  (IEP,ISO)
Experimental Liver Cirrhosis  (IEP,ISO)
Experimental Liver Neoplasms  (ISO)
Experimental Mammary Neoplasms  (ISO)
Experimental Radiation Injuries  (IEP)
Familial Thoracic Aortic Aneurysm 6  (ISO)
Fetal Growth Retardation  (ISO)
gastric ulcer  (IEP)
genetic disease  (ISO)
glaucoma  (ISO)
glomerulonephritis  (ISO)
graft-versus-host disease  (ISO)
Graves' disease  (ISO)
Hashimoto Disease  (ISO)
HELLP syndrome  (IEP,ISO)
hematopoietic system disease  (ISO)
hepatitis B  (ISO)
hepatoblastoma  (ISO)
hepatocellular carcinoma  (IEP,ISO)
heroin dependence  (IEP)
high grade glioma  (ISO)
human immunodeficiency virus infectious disease  (ISO)
Huntington's disease  (ISO)
Hyperoxia  (IEP,ISO)
hypersplenism  (ISO)
Hypothermia  (IEP)
idiopathic pulmonary fibrosis  (ISO)
IgA glomerulonephritis  (IDA)
inclusion body myositis  (ISO)
infectious mononucleosis  (ISO)
Insulin Resistance  (IEP)
intrahepatic cholangiocarcinoma  (ISO)
Kashin-Beck Disease  (ISO)
Kidney Reperfusion Injury  (IEP)
limited scleroderma  (ISO)
liver disease  (IEP)
Liver Injury  (ISO)
Liver Reperfusion Injury  (IEP,IMP)
lung adenocarcinoma  (ISO)
Lung Neoplasms  (ISO)
lupus nephritis  (ISO)
Lymphatic Metastasis  (ISO)
Lymphomatoid Papulosis  (ISO)
lymphoproliferative syndrome  (ISO)
macular degeneration  (ISO)
male infertility  (IEP)
melanoma  (ISO)
Metabolic Brain Diseases  (IEP)
metabolic dysfunction-associated steatotic liver disease  (ISO)
Metabolic Syndrome  (IEP)
mixed connective tissue disease  (ISO)
Moyamoya disease  (ISO)
multiple sclerosis  (ISO)
multiple system atrophy  (ISO)
Multisystemic Smooth Muscle Dysfunction Syndrome  (ISO)
myasthenia gravis  (ISO)
myelodysplastic syndrome  (ISO)
Myocardial Reperfusion Injury  (IDA)
Nasal Polyps  (ISO)
nasal type extranodal NK/T-cell lymphoma  (ISO)
Necrosis  (ISO)
Neoplasm Metastasis  (ISO)
nephritis  (ISO)
ocular hypertension  (IEP)
ovarian cancer  (ISO)
Oxygen-Induced Retinopathy  (ISO)
Parkinson's disease  (ISO)
peripheral vascular disease  (ISO)
Plasmodium falciparum malaria  (ISO)
pre-eclampsia  (ISO)
pre-malignant neoplasm  (IDA)
primary biliary cholangitis  (ISO)
primary cutaneous T-cell non-Hodgkin lymphoma  (ISO)
primary immunodeficiency disease  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (ISO)
proteinuria  (ISO)
Puromycin Aminonucleoside Nephrosis  (IEP)
relapsing-remitting multiple sclerosis  (ISO)
renal cell carcinoma  (ISO)
Reperfusion Injury  (IDA)
retinal detachment  (IEP,IMP)
retinoblastoma  (ISO)
rheumatoid arthritis  (ISO)
sciatic neuropathy  (IEP)
seminoma  (ISO)
Sepsis  (IEP)
Sjogren's syndrome  (ISO,ISS)
Spinal Cord Compression  (ISO)
Spinal Cord Injuries  (IDA,IEP)
Splenomegaly  (ISO)
squamous cell carcinoma  (ISO)
systemic lupus erythematosus  (ISO,ISS)
Taste Disorders  (ISO)
Temporomandibular Joint Osteoarthritis  (IEP)
Testicular Injury  (ISO)
thoracic aortic aneurysm  (ISO)
transient cerebral ischemia  (IDA,IEP,ISO)
transitional cell carcinoma  (ISO)
type 1 diabetes mellitus  (ISO)
type 2 diabetes mellitus  (ISO)
ulcerative colitis  (IEP)
urinary bladder cancer  (ISO)
varicocele  (IEP)
Ventricular Dysfunction, Left  (ISO)
Viral Bronchiolitis  (ISO)
visual epilepsy  (IEP)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-catechin  (ISO)
(-)-anisomycin  (ISO)
(-)-demecolcine  (ISO)
(R)-adrenaline  (ISO)
(R)-lipoic acid  (ISO)
(S)-colchicine  (ISO)
(S)-naringenin  (ISO)
(S)-nicotine  (EXP,ISO)
(Z)-3-butylidenephthalide  (ISO)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (EXP,ISO)
1,2-dichloroethane  (ISO)
1,2-dimethylhydrazine  (EXP,ISO)
1-naphthyl isothiocyanate  (EXP,ISO)
1-nitropropane  (EXP)
15-deoxy-Delta(12,14)-prostaglandin J2  (ISO)
17alpha-ethynylestradiol  (EXP)
17beta-estradiol  (ISO)
17beta-estradiol 3-benzoate  (EXP)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4-D  (EXP,ISO)
2,4-diaminotoluene  (EXP)
2,4-dinitrotoluene  (EXP)
2,6-diaminotoluene  (EXP)
2,6-dinitrotoluene  (EXP)
2-acetamidofluorene  (EXP)
2-amino-2-deoxy-D-glucopyranose 6-phosphate  (ISO)
2-bromohexadecanoic acid  (ISO)
2-nitro-p-phenylenediamine  (EXP)
2-nitropropane  (EXP)
2-nitrotoluene  (EXP)
25-hydroxycholesterol  (ISO)
3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (EXP)
3,3',4,4',5-pentachlorobiphenyl  (ISO)
3,3',5,5'-tetrabromobisphenol A  (EXP)
3,4-methylenedioxymethamphetamine  (ISO)
3-chloropropane-1,2-diol  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
3-methylcholanthrene  (ISO)
3-phenylprop-2-enal  (ISO)
4'-epidoxorubicin  (EXP)
4,4'-diaminodiphenylmethane  (ISO)
4-\{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino\}benzoic acid  (ISO)
4-acetylaminofluorene  (EXP)
4-nitro-1,2-phenylenediamine  (EXP)
4-nitro-m-cresol  (ISO)
4-nitrophenol  (ISO)
4-nonylphenol  (EXP)
4-tert-butylphenol  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-fluorouracil  (ISO)
7,12-dimethyltetraphene  (ISO)
8'-apo-beta,psi-caroten-8'-al  (ISO)
9-cis-retinoic acid  (ISO)
9-Methoxycamptothecin  (ISO)
[6]-Shogaol  (ISO)
acetamide  (EXP)
acetylsalicylic acid  (EXP,ISO)
acrolein  (ISO)
acrylamide  (EXP)
Actein  (EXP)
adefovir pivoxil  (ISO)
aflatoxin B1  (EXP,ISO)
aldehydo-D-glucosamine 6-phosphate  (ISO)
aldehydo-D-glucose  (ISO)
all-trans-4-oxoretinoic acid  (ISO)
all-trans-4-oxoretinol  (ISO)
all-trans-acitretin  (ISO)
all-trans-retinoic acid  (ISO)
all-trans-retinol  (ISO)
Aloe emodin  (ISO)
Aloperine  (EXP)
alpha-naphthoflavone  (ISO)
alpha-pinene  (ISO)
alpinumisoflavone  (ISO)
ammonium chloride  (EXP)
andrographolide  (ISO)
anthocyanin  (EXP)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
anthracen-2-amine  (EXP)
antimycin A  (ISO)
apigenin  (EXP,ISO)
apocynin  (EXP)
arachidonic acid  (ISO)
arecoline  (EXP)
arjunolic acid  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
artesunate  (ISO)
asbestos  (ISO)
atenolol  (ISO)
atorvastatin calcium  (EXP)
atrazine  (ISO)
Aurothioglucose  (ISO)
benazepril  (EXP)
bentonite  (EXP)
benzene-1,2,4-triol  (ISO)
benzo[a]pyrene  (EXP,ISO)
benzo[a]pyrene diol epoxide I  (ISO)
berberine  (ISO)
beta-carotene  (ISO)
beta-D-glucosamine 6-sulfate  (ISO)
Beta-Solamarine  (ISO)
bezafibrate  (EXP,ISO)
bis(2-chloroethyl) sulfide  (ISO)
bis(2-ethylhexyl) phthalate  (EXP,ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bortezomib  (ISO)
bromochloroacetic acid  (EXP)
bucladesine  (EXP)
bufalin  (ISO)
buta-1,3-diene  (ISO)
butyric acid  (ISO)
Cacalol  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (EXP,ISO)
caffeine  (EXP,ISO)
Calcimycin  (ISO)
calcitriol  (ISO)
camptothecin  (ISO)
cannabidiol  (ISO)
capsaicin  (EXP,ISO)
carbamazepine  (ISO)
carbon nanotube  (ISO)
carboplatin  (ISO)
carnosic acid  (ISO)
carvedilol  (ISO)
casticin  (ISO)
catechol  (ISO)
celastrol  (ISO)
celecoxib  (ISO)
cetrorelix  (EXP,ISO)
CGP 52608  (ISO)
charcoal  (EXP)
chlorambucil  (ISO)
chloroacetaldehyde  (ISO)
chloroprene  (ISO)
chlorpromazine  (ISO)
chlorpyrifos  (ISO)
cholesterol  (EXP,ISO)
choline  (ISO)
chromium(6+)  (ISO)
chrysazin  (ISO)
cidofovir anhydrous  (ISO)
Cinobufotalin  (ISO)
cisplatin  (EXP,ISO)
clobetasol  (ISO)
clodronic acid  (ISO)
clofazimine  (EXP)
clofibrate  (ISO)
clorgyline  (ISO)
clotrimazole  (ISO)
clozapine  (ISO)
cobalt atom  (ISO)
cobalt dichloride  (ISO)
cocaine  (ISO)
copanlisib  (ISO)
copper atom  (EXP,ISO)
copper(0)  (EXP,ISO)
copper(II) sulfate  (ISO)
corosolic acid  (ISO)
cortisol  (ISO)
crocidolite asbestos  (EXP,ISO)
Cuprizon  (EXP)
curcumin  (ISO)
cycloheximide  (ISO)
cyclophosphamide  (EXP,ISO)
cyclosporin A  (ISO)
cylindrospermopsin  (ISO)
cypermethrin  (ISO)
cyproconazole  (EXP)
cytarabine  (EXP,ISO)
D-glucose  (ISO)
daunorubicin  (ISO)
decabromodiphenyl ether  (ISO)
deguelin  (ISO)
deoxynivalenol  (EXP)
dexamethasone  (EXP,ISO)
Diallyl sulfide  (ISO)
diallyl trisulfide  (ISO)
diamminedichloroplatinum  (ISO)
diarsenic trioxide  (ISO)
diazinon  (EXP,ISO)
dibenzo[a,l]pyrene  (ISO)
dibenzofurans  (ISO)
dibromoacetic acid  (ISO)
dichlorine  (EXP)
dichlorvos  (ISO)
diclofenac  (ISO)
diethylstilbestrol  (EXP,ISO)
dihydroartemisinin  (EXP)
diisononyl phthalate  (ISO)
Dimethyl phthalate  (EXP)
dimethyl sulfoxide  (ISO)
dimethylarsinic acid  (ISO)
dioscin  (ISO)
diosgenin  (ISO)
dioxygen  (ISO)
diuron  (EXP)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
EC (peptidyl-dipeptidase A) inhibitor  (ISO)
Echimidine  (ISO)
elemental selenium  (ISO)
emodin  (EXP,ISO)
endosulfan  (EXP)
enilconazole  (ISO)
entinostat  (ISO)
epoxiconazole  (EXP,ISO)
esculetin  (ISO)
ethanol  (EXP,ISO)
ethyl methanesulfonate  (ISO)
etoposide  (ISO)
fenofibrate  (EXP,ISO)
ferrosoferric oxide  (ISO)
fingolimod hydrochloride  (ISO)
flavanone  (ISO)
flavonoids  (ISO)
flutamide  (EXP)
folic acid  (ISO)
formaldehyde  (EXP,ISO)
fotemustine  (ISO)
fructose  (EXP,ISO)
fulvestrant  (ISO)
Fulvic acid  (ISO)
fumonisin B1  (ISO)
furan  (EXP)
Fusarenone X  (ISO)
gamma-hexachlorocyclohexane  (EXP)
gemcitabine  (ISO)
genistein  (EXP,ISO)
gentamycin  (EXP)
gibberellin A3  (EXP)
gingerol  (ISO)
ginsenoside Re  (ISO)
glucose  (ISO)
glutathione  (ISO)
glutathione disulfide  (ISO)
glyphosate  (ISO)
gold atom  (ISO)
gold(0)  (ISO)
gossypol  (EXP)
GSK690693  (ISO)
guggulsterone  (EXP)
GW 4064  (EXP)
Heliotrine  (EXP,ISO)
heparin  (ISO)
heroin  (ISO)
hexachlorobenzene  (EXP)
hexadecanoic acid  (EXP,ISO)
Honokiol  (EXP)
hydrogen peroxide  (EXP,ISO)
hydrogen sulfide  (ISO)
hydroquinone  (ISO)
hydroxychloroquine  (ISO)
hydroxyurea  (ISO)
hyperforin  (ISO)
ibuprofen  (ISO)
ICI D1694  (ISO)
idelalisib  (ISO)
inulin  (ISO)
irinotecan  (ISO)
isoflavones  (EXP)
isoprenaline  (EXP,ISO)
isosilybin  (ISO)
ivermectin  (ISO)
ketoconazole  (EXP,ISO)
L-methionine  (ISO)
lansoprazole  (EXP)
Lasiocarpine  (ISO)
lead diacetate  (ISO)
lead(0)  (ISO)
leukotriene D4  (ISO)
Licochalcone A  (ISO)
lipoic acid  (ISO)
lipopolysaccharide  (EXP,ISO)
lithium atom  (ISO)
lithium hydride  (ISO)
lithocholic acid  (ISO)
lovastatin  (EXP,ISO)
luteolin  (EXP)
luteolin 7-O-beta-D-glucoside  (ISO)
LY294002  (ISO)
magnesium oxide  (ISO)
maneb  (ISO)
manganese(II) chloride  (EXP)
mangiferin  (ISO)
masoprocol  (ISO)
medroxyprogesterone acetate  (ISO)
melatonin  (EXP,ISO)
melittin  (ISO)
menadione  (ISO)
mercury atom  (ISO)
mercury dibromide  (ISO)
mercury dichloride  (ISO)
mercury(0)  (ISO)
metformin  (EXP)
methamphetamine  (EXP)
methotrexate  (ISO)
methoxychlor  (EXP)
methyl methanesulfonate  (ISO)
methylarsonic acid  (ISO)
methylmercury chloride  (ISO)
methyltestosterone  (EXP)
mifepristone  (ISO)
miquelianin  (EXP)
mitogen  (ISO)
mitomycin C  (ISO)
mitoxantrone  (ISO)
MK-2206  (ISO)
montelukast  (ISO)
morin  (EXP)
morphine  (ISO)
Morroniside  (ISO)
myriocin  (ISO)
Myrtucommulone A  (ISO)
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide  (EXP)
N-acetyl-L-cysteine  (EXP,ISO)
N-methyl-4-phenylpyridinium  (EXP)
N-nitrosodiethylamine  (EXP,ISO)
N-Nitrosopyrrolidine  (ISO)
naproxen  (EXP)
naringin  (ISO)
nickel atom  (ISO)
nickel dichloride  (EXP)
niclosamide  (EXP,ISO)
nicotine  (EXP,ISO)
nitric oxide  (ISO)
nitrobenzene  (ISO)
nitroglycerin  (ISO)
Nodularin  (ISO)
notoginsenoside R1  (ISO)
Nutlin-3  (ISO)
nystatin  (ISO)
obeticholic acid  (EXP)
ochratoxin A  (EXP,ISO)
octreotide  (ISO)
okadaic acid  (ISO)
oleic acid  (EXP,ISO)
olmesartan  (ISO)
orlistat  (ISO)
osthole  (ISO)
ouabain  (ISO)
ozone  (EXP,ISO)
p-menthan-3-ol  (ISO)
paclitaxel  (ISO)
Panduratin A  (ISO)
paracetamol  (EXP,ISO)
paraquat  (ISO)
parthenolide  (ISO)
pemetrexed  (ISO)
Pendulone  (ISO)
Pentoxifylline  (ISO)
perfluorodecanoic acid  (ISO)
perfluorohexanesulfonic acid  (ISO)
perfluorononanoic acid  (EXP)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (ISO)
perfluoroundecanoic acid  (ISO)
perifosine  (ISO)
permethrin  (ISO)
phenethyl caffeate  (ISO)
phenobarbital  (ISO)
phenol  (ISO)
phenylmercury acetate  (ISO)
phlorizin  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
phoxim  (ISO)
picoxystrobin  (ISO)
pinostrobin  (ISO)
pirinixic acid  (ISO)
platycodin D  (ISO)
plumbagin  (ISO)
potassium bromate  (ISO)
pregnenolone 16alpha-carbonitrile  (EXP)
prochloraz  (EXP)
procyanidin B3  (ISO)
propanal  (ISO)
propiconazole  (ISO)
propofol  (ISO)
propranolol  (EXP)
prostaglandin E2  (ISO)
pterostilbene  (ISO)
pyrethrins  (ISO)
quercetin  (EXP,ISO)
quercitrin  (ISO)
reactive oxygen species  (ISO)
regorafenib  (ISO)
resveratrol  (EXP,ISO)
ribavirin  (ISO)
riddelliine  (EXP)
rifampicin  (ISO)
risperidone  (ISO)
Roridin A  (ISO)
rotenone  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
S-allylcysteine  (ISO)
S-butyl-DL-homocysteine (S,R)-sulfoximine  (EXP)
sanguinarine  (ISO)
SB 203580  (ISO)
SB 415286  (ISO)
SB 431542  (ISO)
selenium atom  (ISO)
senecionine  (EXP,ISO)
Senkirkine  (ISO)
silicon dioxide  (EXP,ISO)
sirolimus  (ISO)
sodium arsenite  (EXP,ISO)
sodium dichromate  (EXP)
sodium fluoride  (ISO)
Soman  (EXP)
sorafenib  (ISO)
streptozocin  (EXP)
succimer  (ISO)
sucrose  (EXP)
Suillin  (ISO)
sulforaphane  (ISO)
sumatriptan  (EXP)
tacrolimus hydrate  (ISO)
tamibarotene  (ISO)
taurine  (ISO)
tauroursodeoxycholic acid  (EXP)
terbufos  (ISO)
tert-butyl hydroperoxide  (ISO)
testosterone  (EXP)
tetrachloromethane  (EXP,ISO)
tetracycline  (ISO)
tetrazolium violet  (ISO)
thalidomide  (EXP,ISO)
thapsigargin  (ISO)
thiazoles  (ISO)
thimerosal  (ISO)
thioacetamide  (EXP)
thiosalicylic acid  (EXP)
thymol  (EXP)
thymol sulfate(1-)  (EXP)
titanium dioxide  (EXP,ISO)
tolclofos-methyl  (ISO)
toluene  (EXP)
Tomentosin  (ISO)
topotecan  (ISO)
transplatin  (ISO)
tributylstannane  (EXP)
Tributyltin oxide  (ISO)
trichloroethene  (EXP)
trichostatin A  (ISO)
triclosan  (ISO)
trimethyltin  (ISO)
triphenyl phosphate  (EXP)
Triptolide  (ISO)
troglitazone  (EXP,ISO)
tubocurarine  (ISO)
Tungsten carbide  (ISO)
tunicamycin  (ISO)
urethane  (ISO)
valproic acid  (ISO)
valsartan  (EXP)
vanillic acid  (EXP)
vinclozolin  (EXP)
vincristine  (ISO)
vinorelbine  (ISO)
vismodegib  (ISO)
vorinostat  (ISO)
withaferin A  (EXP)
wortmannin  (ISO)
Y-27632  (ISO)
zearalenone  (EXP)
zidovudine  (ISO)
zinc atom  (ISO)
zinc oxide  (ISO)
zinc(0)  (ISO)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
activation-induced cell death of T cells  (IBA,IEA,ISO)
apoptotic process  (ISO)
apoptotic signaling pathway  (IMP,ISO)
B cell mediated immunity  (ISO)
cellular response to amino acid starvation  (ISO)
cellular response to cobalt ion  (IEP)
cellular response to cytokine stimulus  (IEP)
cellular response to estrogen stimulus  (IEP)
cellular response to glucose stimulus  (IEP)
cellular response to hydrogen peroxide  (IEP)
cellular response to hydrostatic pressure  (IEP)
cellular response to hyperoxia  (ISO)
cellular response to hypoxia  (IEP)
cellular response to interleukin-1  (IEP)
cellular response to lithium ion  (ISO)
cellular response to mechanical stimulus  (ISO)
cellular response to organic cyclic compound  (IEP)
cellular response to phenylalanine  (IEP)
cellular response to tumor necrosis factor  (IEP)
cellular response to type II interferon  (IEP)
chordate embryonic development  (IEP)
circadian rhythm  (ISO)
dendrite regeneration  (IMP)
extrinsic apoptotic signaling pathway  (ISO)
extrinsic apoptotic signaling pathway in absence of ligand  (IBA,IEA,ISO)
extrinsic apoptotic signaling pathway via death domain receptors  (ISO)
Fas signaling pathway  (ISO)
gene expression  (ISO)
hepatocyte apoptotic process  (ISO)
immune response  (IEA)
inflammatory cell apoptotic process  (ISO)
liver regeneration  (IEP)
lymphocyte apoptotic process  (ISO)
maternal process involved in female pregnancy  (IEP)
motor neuron apoptotic process  (IBA,IEA,ISO)
necroptotic signaling pathway  (IBA,IEA,ISO)
negative regulation of apoptotic process  (IBA,IEA,ISO)
negative regulation of B cell activation  (ISO)
negative regulation of Schwann cell migration  (IMP)
negative regulation of Schwann cell proliferation  (IMP)
negative thymic T cell selection  (ISO)
neuron apoptotic process  (ISO)
ovarian follicle atresia  (IEP)
ovulation cycle  (IEP)
positive regulation of apoptotic process  (IMP,ISO)
positive regulation of apoptotic signaling pathway  (ISO)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process  (IMP)
positive regulation of neuron apoptotic process  (IMP)
positive regulation of protein phosphorylation  (ISO)
positive regulation of protein-containing complex assembly  (ISO)
regulation of apoptotic process  (IMP)
regulation of B cell differentiation  (ISO)
regulation of cell population proliferation  (IMP)
regulation of hematopoietic progenitor cell differentiation  (ISO)
regulation of lipid storage  (IEP)
regulation of myeloid cell differentiation  (ISO)
regulation of stress-activated MAPK cascade  (IBA,IEA,ISO)
regulation of T cell differentiation  (ISO)
response to cycloheximide  (IEP)
response to cytokine  (IEP)
response to estrogen  (IEP)
response to ethanol  (IEP)
response to fluoride  (IEP)
response to glucocorticoid  (ISO)
response to growth factor  (IEP)
response to hypoxia  (IEP)
response to inorganic substance  (IEP)
response to ischemia  (IEP)
response to lipopolysaccharide  (IEP)
response to nutrient levels  (IEP)
response to organic cyclic compound  (IEP)
response to peptide hormone  (IEP)
response to toxic substance  (IEP,ISO)
response to xenobiotic stimulus  (IEP)
spermatogenesis  (IEP)
spleen development  (ISO)
T cell homeostasis  (ISO)
telencephalon development  (IEP)
tumor necrosis factor-mediated signaling pathway  (IEA)

Cellular Component


References - curated
# Reference Title Reference Citation
1. Inhibition of Fas-mediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury. Ackery A, etal., J Neurotrauma. 2006 May;23(5):604-16.
2. Samsum Ant Venom Exerts Anticancer Activity Through Immunomodulation In Vitro and In Vivo. Al-Tamimi J, etal., Cancer Biother Radiopharm. 2018 Mar;33(2):65-73. doi: 10.1089/cbr.2017.2400.
3. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia. Amasaki Y, etal., Clin Exp Immunol. 1995 Feb;99(2):245-50.
4. Fas antigen (CD95) expression in peripheral blood progenitor cells from patients with leukaemia and lymphoma. Anthony RS, etal., Leuk Lymphoma. 1998 Aug;30(5-6):449-58.
5. Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. Ares-Carrasco S, etal., Am J Physiol Heart Circ Physiol. 2009 Oct 9.
6. Expression of Fas and Fas ligand in human testicular germ cell tumours. Baldini E, etal., Int J Androl. 2007 Oct 3;.
7. Regulation of FasL/Fas in human trophoblasts: possible implications for chorioamnionitis. Balkundi DR, etal., Biol Reprod. 2003 Aug;69(2):718-24. Epub 2003 Apr 16.
8. Apoptosis of tubular epithelial cells in glycogen nephrosis during diabetes. Bamri-Ezzine S, etal., Lab Invest. 2003 Jul;83(7):1069-80.
9. CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients. Baryshnikov AYu, etal., Adv Exp Med Biol. 1999;457:251-8.
10. Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread. Bebenek M, etal., Anticancer Res. 2007 Jan-Feb;27(1A):215-8.
11. Increased placental apoptosis in maternal food restricted gestations: role of the Fas pathway. Belkacemi L, etal., Placenta. 2009 Sep;30(9):739-51. doi: 10.1016/j.placenta.2009.06.003. Epub 2009 Jul 18.
12. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Bettinardi A, etal., Blood. 1997 Feb 1;89(3):902-9.
13. Expression of Fas-Fas ligand antigens and apoptotic marker APO2.7 by the human conjunctival epithelium. Positive correlation with class II HLA DR expression in inflammatory ocular surface disorders. Brignole F, etal., Exp Eye Res. 1998 Dec;67(6):687-97.
14. FAS deficiency reduces apoptosis, spares axons and improves function after spinal cord injury. Casha S, etal., Exp Neurol. 2005 Dec;196(2):390-400. Epub 2005 Oct 3.
15. The Fas system may have a role in male reproduction. Celik-Ozenci C, etal., Fertil Steril. 2006 Apr;85 Suppl 1:1168-78.
16. Tributyltin impacts in metabolic syndrome development through disruption of angiotensin II receptor signaling pathways in white adipose tissue from adult female rats. Ceotto Freitas-Lima L, etal., Toxicol Lett. 2018 Aug 29. pii: S0378-4274(18)31826-5. doi: 10.1016/j.toxlet.2018.08.018.
17. The extracellular matrix, p53 and estrogen compete to regulate cell-surface Fas/Apo-1 suicide receptor expression in proliferating embryonic cerebral cortical precursors, and reciprocally, Fas-ligand modifies estrogen control of cell-cycle proteins. Cheema ZF, etal., BMC Neurosci. 2004 Mar 23;5:11.
18. Fas/Apo -1 and associated proteins in the differentiating cerebral cortex: induction of caspase-dependent cell death and activation of NF-kappaB. Cheema ZF, etal., J Neurosci. 1999 Mar 1;19(5):1754-70.
19. Cross-Talk between Fas/Fas ligand system and nitric oxide in the pathway subserving granulosa cell apoptosis: a possible regulatory mechanism for ovarian follicle atresia. Chen Q, etal., Endocrinology 2005 Feb;146(2):808-15. Epub 2004 Nov 4.
20. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome. Choi Y, etal., Clin Immunol. 1999 Oct;93(1):34-45.
21. Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. Christensson M, etal., J Clin Immunol. 2002 Jul;22(4):220-7.
22. Multiple actions of pifithrin-alpha on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells. Chua CC, etal., Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2606-13.
23. Oncogenomics of c-Myc transgenic mice reveal novel regulators of extracellular signaling, angiogenesis and invasion with clinical significance for human lung adenocarcinoma. Ciribilli Y and Borlak J, Oncotarget. 2017 Oct 23;8(60):101808-101831. doi: 10.18632/oncotarget.21981. eCollection 2017 Nov 24.
24. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Coppola D, etal., Ann Surg Oncol. 1999 Apr-May;6(3):298-304.
25. Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance. Cosson E, etal., Diabetes Metab. 2005 Feb;31(1):47-54.
26. Disruption of the FasL/Fas axis protects against inflammation-derived tumorigenesis in chronic liver disease. Cubero FJ, etal., Cell Death Dis. 2019 Feb 8;10(2):115. doi: 10.1038/s41419-019-1391-x.
27. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. Cudrici C, etal., J Immunol. 2006 Mar 1;176(5):3173-80.
28. Umbilical cord blood stem cell mediated downregulation of fas improves functional recovery of rats after spinal cord injury. Dasari VR, etal., Neurochem Res. 2008 Jan;33(1):134-49. Epub 2007 Aug 17.
29. FasL, Fas, and death-inducing signaling complex (DISC) proteins are recruited to membrane rafts after spinal cord injury. Davis AR, etal., J Neurotrauma. 2007 May;24(5):823-34.
30. Fas antigen/CD-95 upregulation and activation during castration-induced regression of the rat ventral prostate gland. de la Taille A, etal., Prostate. 1999 Jul 1;40(2):89-96.
31. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. Dowling P, etal., J Exp Med. 1996 Oct 1;184(4):1513-8.
32. A critical role for Fas/CD-95 dependent signaling pathways in the pathogenesis of hyperoxia-induced brain injury. Dzietko M, etal., Ann Neurol. 2008 Dec;64(6):664-73. doi: 10.1002/ana.21516.
33. Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia. Edathara PM, etal., Tumour Biol. 2015 Nov 13.
34. H(2)O(2) induces upregulation of Fas and Fas ligand expression in NGF-differentiated PC12 cells: modulation by cAMP. Facchinetti F, etal., J Neurosci Res 2002 Jul 15;69(2):178-88.
35. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. Farre L, etal., J Leukoc Biol. 2008 Jan;83(1):220-2. Epub 2007 Oct 25.
36. Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Ferrer I, etal., Neuropathol Appl Neurobiol. 2000 Oct;26(5):424-33.
37. apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding of a positive association for a polymorphism in the TNFRSF6 gene. Feuk L, etal., Hum Genet 2000 Oct;107(4):391-6.
38. Murine cytomegalovirus induces a Sjogren's syndrome-like disease in C57Bl/6-lpr/lpr mice. Fleck M, etal., Arthritis Rheum. 1998 Dec;41(12):2175-84.
39. Tumor Fas (APO-1/CD95) up-regulation results in increased apoptosis and survival times for rats with intracranial malignant gliomas. Frankel B, etal., Neurosurgery. 2001 Jul;49(1):168-75; discussion 175-6.
40. Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome. Fujihara T, etal., Clin Rheumatol. 1998;17(6):496-9.
41. Upregulation of Fas/Fas ligand in inclusion body myositis. Fyhr IM and Oldfors A, Ann Neurol. 1998 Jan;43(1):127-30.
42. Fas/FasL play a central role in pancreatitis-induced hepatocyte apoptosis. Gallagher SF, etal., J Gastrointest Surg. 2005 Apr;9(4):467-74; discussion 474-5. doi: 10.1016/j.gassur.2004.12.008.
43. The protective role of hydrogen sulfide in myocardial ischemia-reperfusion-induced injury in diabetic rats. Gao Y, etal., Int J Cardiol. 2011 Oct 20;152(2):177-83. doi: 10.1016/j.ijcard.2010.07.012. Epub 2011 Feb 12.
44. Modulation of Fas receptor proteins and dynamin during opiate addiction and induction of opiate withdrawal in rat brain. Garcia-Fuster MJ, etal., Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):421-31. Epub 2003 Oct 3.
45. Blood-soluble Fas levels are increased in type 2 diabetic patients with peripheral vascular disease. Garcia-Unzueta MT, etal., Horm Metab Res. 2006 Oct;38(10):673-7.
46. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
47. Dysregulation of the Fas/FasL system in an experimental animal model of HELLP syndrome. Gibbens J, etal., Pregnancy Hypertens. 2017 Apr;8:26-30. doi: 10.1016/j.preghy.2017.02.004. Epub 2017 Feb 24.
48. Neutrophil gelatinase-associated lipocalin protects renal tubular epithelial cell in ischemic/reperfusion injury rats via apoptosis-regulating proteins. Gong L, etal., Ren Fail. 2012;34(6):777-83. doi: 10.3109/0886022X.2012.678173. Epub 2012 Apr 16.
49. miR-411 suppresses acute spinal cord injury via downregulation of Fas ligand in rats. Gong ZM, etal., Biochem Biophys Res Commun. 2018 Jun 22;501(2):501-506. doi: 10.1016/j.bbrc.2018.05.022. Epub 2018 May 16.
50. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Gratas C, etal., Cancer Res. 1998 May 15;58(10):2057-62.
51. In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1. Gravekamp C, etal., Cancer Immunol Immunother. 2007 Dec 20;.
52. Clinical relevance of CD95 (Fas/Apo-1) on T cells of patients with B-cell chronic lymphocytic leukemia. Groneberg C, etal., Exp Hematol. 2003 Aug;31(8):682-5.
53. Fas/APO-1/CD95 system as a mediator of granulosa cell apoptosis in ovarian follicle atresia. Hakuno N, etal., Endocrinology. 1996 May;137(5):1938-48.
54. Levels of soluble Fas/APO-1 in patients with Behcet's disease. Hamzaoui K, etal., Mediators Inflamm. 1998;7(2):111-4.
55. Double role of Fas ligand in the apoptosis of intervertebral disc cells in vitro. Han D, etal., Acta Biochim Biophys Sin (Shanghai). 2009 Nov;41(11):938-47.
56. Insulitis in human type 1 diabetes. Hanafusa T and Imagawa A, Ann N Y Acad Sci. 2008 Dec;1150:297-9.
57. T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis. Hao Z, etal., J Exp Med. 2004 May 17;199(10):1355-65.
58. Pentoxifylline attenuates cytokine stress and Fas system in syngeneic liver proteins induced experimental autoimmune hepatitis. Hendawy N, Biomed Pharmacother. 2017 Aug;92:316-323. doi: 10.1016/j.biopha.2017.05.084. Epub 2017 May 25.
59. Apoptosis in surgically excised choroidal neovascular membranes in age-related macular degeneration. Hinton DR, etal., Arch Ophthalmol. 1998 Feb;116(2):203-9.
60. Fas/Fas-ligand expressions in peripheral-blood mononuclear cells of patients with myelodysplastic syndromes. Hirano T, etal., Res Commun Mol Pathol Pharmacol. 2003;113-114:315-28.
61. Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Hou XW, etal., Cardiovasc Drugs Ther. 2006 Apr;20(2):85-91.
62. Tumor necrosis factor alpha and interleukin 1beta up-regulate gastric mucosal Fas antigen expression in Helicobacter pylori infection. Houghton J, etal., Infect Immun. 2000 Mar;68(3):1189-95.
63. The Fas/Fas ligand death receptor pathway contributes to phenylalanine-induced apoptosis in cortical neurons. Huang X, etal., PLoS One. 2013 Aug 7;8(8):e71553. doi: 10.1371/journal.pone.0071553. Print 2013.
64. FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymph node metastases. Ioachim HL, etal., Pathol Res Pract. 2005;200(11-12):743-51.
65. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. Itoh N, etal., J Exp Med. 1997 Aug 18;186(4):613-8.
66. The role of Fas-Fas ligand-mediated apoptosis in autoimmune lacrimal gland disease in MRL/MpJ mice. Jabs DA, etal., Invest Ophthalmol Vis Sci. 2001 Feb;42(2):399-401.
67. Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes. Jaita G, etal., Endocrinology. 2005 Nov;146(11):4737-44. Epub 2005 Aug 11.
68. Non-viral systemic delivery of Fas siRNA suppresses cyclophosphamide-induced diabetes in NOD mice. Jeong JH, etal., J Control Release. 2009 Dec 14.
69. Anti-apoptosis effects of oxymatrine protect the liver from warm ischemia reperfusion injury in rats. Jiang H, etal., World J Surg. 2005 Nov;29(11):1397-401.
70. [Expression and distribution of Fas and Fas-L in the nasal polyps]. Jin H, etal., Zhonghua Er Bi Yan Hou Ke Za Zhi. 2004 Mar;39(3):143-6.
71. Retinal glial cell responses and Fas/FasL activation in rats with chronic ocular hypertension. Ju KR, etal., Brain Res. 2006 Nov 29;1122(1):209-21. Epub 2006 Oct 11.
72. Involvement of mitochondrial- and Fas-mediated dual mechanism in CoCl2-induced apoptosis of rat PC12 cells. Jung JY and Kim WJ, Neurosci Lett. 2004 Nov 23;371(2-3):85-90.
73. FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Kang S, etal., Cancer Genet Cytogenet. 2008 Jan 1;180(1):1-5.
74. Expression of Fas and Fas ligand mRNA in rat and human preimplantation embryos. Kawamura K, etal., Mol Hum Reprod. 2001 May;7(5):431-6.
75. Fas (APO-1/CD95) mRNA is down-regulated in liver regeneration after hepatectomy in rats. Kiba T, etal., J Gastroenterol. 2000;35(1):34-8.
76. Metabolic loading of guanosine induces chondrocyte apoptosis via the Fas pathway. Kim DJ, etal., Exp Mol Med. 2006 Aug 31;38(4):401-7.
77. The apoptotic effects of oxidative stress and antiapoptotic effects of caspase inhibitors on rat notochordal cells. Kim KW, etal., Spine (Phila Pa 1976). 2007 Oct 15;32(22):2443-8.
78. Rapid induction of Fas antigen mRNA expression in vivo by cycloheximide. Kimura K and Yamamoto M, Cell Biochem Funct. 1997 Jun;15(2):81-6.
79. A variant mRNA species encoding a truncated form of Fas antigen in the rat liver. Kimura K, etal., Biochem Biophys Res Commun 1994 Jan 28;198(2):666-74.
80. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Kitagawa M, etal., Leukemia. 1998 Apr;12(4):486-92.
81. Expression of functional Fas antigen on adult T-cell leukemia. Kotani T, etal., Leuk Res. 1994 Apr;18(4):305-10.
82. FAS-dependent cell death in alpha-synuclein transgenic oligodendrocyte models of multiple system atrophy. Kragh CL, etal., PLoS One. 2013;8(1):e55243. doi: 10.1371/journal.pone.0055243. Epub 2013 Jan 25.
83. Liver-specific Fas silencing prevents galactosamine/lipopolysaccharide-induced liver injury. Kuhla A, etal., Apoptosis. 2015 Apr;20(4):500-11. doi: 10.1007/s10495-015-1088-2.
84. Expression levels of FAS are regulated through an evolutionary conserved element in intron 2, which modulates cystic fibrosis disease severity. Kumar V, etal., Genes Immun. 2008 Dec;9(8):689-96. doi: 10.1038/gene.2008.63. Epub 2008 Aug 7.
85. Fas ligand is enriched in the caveolae membrane domains of thymic epithelial cells. Lalor D, etal., Cell Immunol 2004 Jul;230(1):10-6.
86. Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation. Laskowska M, etal., Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):155-9. Epub 2005 Sep 19.
87. The Fas system is a key regulator of germ cell apoptosis in the testis. Lee J, etal., Endocrinology. 1997 May;138(5):2081-8.
88. The Fas system, a regulator of testicular germ cell apoptosis, is differentially up-regulated in Sertoli cell versus germ cell injury of the testis. Lee J, etal., Endocrinology. 1999 Feb;140(2):852-8.
89. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD. Lee S, etal., Bone Marrow Transplant. 1997 Nov;20(10):883-8.
90. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Lee SH, etal., Hum Pathol. 2001 Mar;32(3):250-6. doi: 10.1053/hupa.2001.22769.
91. In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas. Lee SH, etal., J Pathol. 1999 Jun;188(2):207-12. doi: 10.1002/(SICI)1096-9896(199906)188:2<207::AID-PATH337>3.0.CO;2-8.
92. Associations between the FAS -670 A/G and -1,377 G/A polymorphisms and susceptibility to autoimmune rheumatic diseases: a meta-analysis. Lee YH, etal., Mol Biol Rep. 2012 Dec;39(12):10671-9. doi: 10.1007/s11033-012-1957-5. Epub 2012 Oct 5.
93. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Li C, etal., Pharmacogenet Genomics. 2006 Apr;16(4):245-51.
94. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Li C, etal., Pharmacogenet Genomics. 2006 Apr;16(4):253-63.
95. Fas Ag-FasL coupling leads to ERK1/2-mediated proliferation of gastric mucosal cells. Li H, etal., Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G263-75. Epub 2007 Nov 8.
96. Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats. Li J, etal., Diabetol Metab Syndr. 2017 Dec 1;9:94. doi: 10.1186/s13098-017-0289-y. eCollection 2017.
97. Alleviation of ischemia-reperfusion injury in rat liver transplantation by induction of small interference RNA targeting Fas. Li X, etal., Langenbecks Arch Surg. 2007 May;392(3):345-51. Epub 2007 Jan 19.
98. Fas Ligand Gene (Faslg) Plays an Important Role in Nerve Degeneration and Regeneration After Rat Sciatic Nerve Injury. Li Y, etal., Front Mol Neurosci. 2018 Jun 19;11:210. doi: 10.3389/fnmol.2018.00210. eCollection 2018.
99. The role of impaired insulin/IGF action in primary diabetic encephalopathy. Li ZG, etal., Brain Res. 2005 Mar 10;1037(1-2):12-24.
100. Prophylactic efficacy of patchoulene epoxide against ethanol-induced gastric ulcer in rats: Influence on oxidative stress, inflammation and apoptosis. Liang J, etal., Chem Biol Interact. 2018 Mar 1;283:30-37. doi: 10.1016/j.cbi.2018.01.014. Epub 2018 Jan 12.
101. Association between FAS polymorphism and prostate cancer development. Lima L, etal., Prostate Cancer Prostatic Dis. 2008;11(1):94-8. Epub 2007 Jul 31.
102. [Regulation of sishen wan on Bax/Bcl-2 mRNA, Fas/FasL in colonic tissue from rats with colitis]. Liu D, etal., Zhongguo Zhong Yao Za Zhi. 2011 Dec;36(24):3484-8.
103. FasL shedding is reduced by hypothermia in experimental stroke. Liu L, etal., J Neurochem. 2008 Jul;106(2):541-50. Epub 2008 Apr 12.
104. [The relationship between expression of fas mRNA and apoptosis after traumatic brain injury in rats and the role of GM-1 in protecting the brain] Liu QJ, etal., Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Jul;36(4):477-9.
105. Effects of apigenin on the expression levels of B-cell lymphoma-2, Fas and Fas ligand in renal ischemia-reperfusion injury in rats. Liu Y, etal., Exp Ther Med. 2017 Dec;14(6):5345-5354. doi: 10.3892/etm.2017.5241. Epub 2017 Oct 2.
106. Up-regulation of CD95 (Apo-1/Fas) is associated with spermatocyte apoptosis during the first round of spermatogenesis in the rat. Lizama C, etal., Apoptosis. 2007 Mar;12(3):499-512. Epub 2006 Dec 29.
107. The death ligand TRAIL in diabetic nephropathy. Lorz C, etal., J Am Soc Nephrol. 2008 May;19(5):904-14. Epub 2008 Feb 20.
108. NFAT-1 hyper-activation by methionine enkephalin (MENK) significantly induces cell apoptosis of rats C6 glioma in vivo and in vitro. Lu WC, etal., Int Immunopharmacol. 2018 Mar;56:1-8. doi: 10.1016/j.intimp.2018.01.005. Epub 2018 Jan 9.
109. A study of promoter and intronic markers of ApoI/Fas gene and the interaction with Fas ligand in relapsing multiple sclerosis. Lucas M, etal., Eur Neurol. 2004;52(1):12-7. Epub 2004 Jun 22.
110. Thyrotropin releasing hormone (TRH) affects gene expression in pancreatic beta-cells. Luo L and Yano N, Endocr Res. 2005;31(3):185-98.
111. Fas inhibition attenuates lipopolysaccharide-induced apoptosis and cytokine release of rat type II alveolar epithelial cells. Ma X, etal., Mol Biol Rep. 2010 Oct;37(7):3051-6. doi: 10.1007/s11033-009-9876-9. Epub 2009 Oct 13.
112. [Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125]. Ma YX, etal., Zhonghua Yi Xue Za Zhi. 2007 Mar 20;87(11):734-9.
113. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Maciejewski JP, etal., Br J Haematol. 1995 Sep;91(1):245-52.
114. Aging correlates with decreased beta-cell proliferative capacity and enhanced sensitivity to apoptosis: a potential role for Fas and pancreatic duodenal homeobox-1. Maedler K, etal., Diabetes. 2006 Sep;55(9):2455-62.
115. Up-regulated expression of Fas antigen in peripheral T cell subsets in patients with myasthenia gravis. Mai W, etal., Clin Invest Med. 2012 Oct 6;35(5):E294.
116. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Martin DA, etal., Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4552-7.
117. Increased intensities of fas expression on peripheral T-cell subsets in severe autoimmune thyroid disease. Maruoka H, etal., Thyroid. 2004 Jun;14(6):417-23.
118. Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Maruyama R, etal., Br J Cancer. 2006 Nov 6;95(9):1244-9. Epub 2006 Oct 10.
119. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. McDonnell TJ, etal., BMC Med Genomics. 2008 Jan 31;1:1.
120. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
121. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Mizutani Y, etal., Cancer Biother Radiopharm. 2002 Oct;17(5):563-7.
122. Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis. Molica S, etal., Haematologica. 1996 Jul-Aug;81(4):302-9.
123. Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation. Müschen M, etal., Gastroenterology. 1999 Mar;116(3):666-77. doi: 10.1016/s0016-5085(99)70189-7.
124. Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha. Nagai Y, etal., Am J Physiol Endocrinol Metab 2002 May;282(5):E1180-90.
125. Blockade of the Fas/Fas ligand interaction suppresses hepatocyte apoptosis in ischemia-reperfusion rat liver. Nakajima H, etal., Apoptosis. 2008 Aug;13(8):1013-21. doi: 10.1007/s10495-008-0234-5.
126. Insufficient expression of Fas antigen on helper T cells in Behcet's disease. Nakamura S, etal., Br J Ophthalmol. 1996 Feb;80(2):174-6.
127. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
128. Amelioration of systemic autoimmune disease by the stimulation of apoptosis-promoting receptor Fas with anti-Fas mAb. Nishimura-Morita Y, etal., Int Immunol. 1997 Dec;9(12):1793-9.
129. Blocking Daxx trafficking attenuates neuronal cell death following ischemia/reperfusion in rat hippocampus CA1 region. Niu YL, etal., Arch Biochem Biophys. 2011 Nov;515(1-2):89-98. doi: 10.1016/j.abb.2011.07.016. Epub 2011 Aug 6.
130. Soluble Fas in serum from patients with renal cell carcinoma. Nonomura N, etal., Urology. 2000 Jan;55(1):151-5.
131. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Nozawa K, etal., Arthritis Rheum. 1997 Jun;40(6):1126-9.
132. ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model. Odani-Kawabata N, etal., BMC Musculoskelet Disord. 2010 Sep 27;11:221. doi: 10.1186/1471-2474-11-221.
133. Fas-mediated apoptosis in human lens epithelial cells of cataracts associated with diabetic retinopathy. Okamura N, etal., Med Electron Microsc. 2002 Dec;35(4):234-41.
134. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
135. [Effect of atorvastatin on Fas (CD95/Apo-1) expression in normal or ischemic brain] Oria de Suarez C, etal., An Med Interna. 2006 Apr;23(4):156-60.
136. Protecting mechanism of puerarin on the brain neurocyte of rat in acute local ischemia brain injury and local cerebral ischemia-reperfusion injury. Pan HP and Li G, Yakugaku Zasshi. 2008 Nov;128(11):1689-98.
137. Expression of FasL and its interaction with Fas are mediated by c-Jun N-terminal kinase (JNK) pathway in 6-OHDA-induced rat model of Parkinson disease. Pan J, etal., Neurosci Lett. 2007 Nov 27;428(2-3):82-7. Epub 2007 Sep 25.
138. Protein kinase C-zeta (PKC-zeta) regulates Kupffer cell apoptosis during experimental sepsis. Peng Y, etal., J Gastrointest Surg. 2007 Dec;11(12):1712-21. Epub 2007 Sep 25.
139. Nuclear factor-kappaB mediates Kupffer cell apoptosis through transcriptional activation of Fas/FasL. Peng Y, etal., J Surg Res. 2006 Jan;130(1):58-65. Epub 2005 Sep 8.
140. Apoptotic mechanisms within the retina in Staphylococcus epidermidis experimental endophthalmitis. Pharmakakis NM, etal., Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):667-74. doi: 10.1007/s00417-008-0996-z. Epub 2008 Nov 28.
141. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
142. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
143. FAS A-670G and Fas ligand IVS2nt A 124G polymorphisms are significantly increased in women with pre-eclampsia and may contribute to HELLP syndrome: a case-controlled study. Raguema N, etal., BJOG. 2018 Dec;125(13):1758-1764. doi: 10.1111/1471-0528.15412. Epub 2018 Sep 3.
144. Amplification of CD95 activation by caspase 8-induced endosomal acidification in rat hepatocytes. Reinehr R, etal., J Biol Chem. 2008 Jan 25;283(4):2211-22. Epub 2007 Nov 28.
145. [The expression of Fas antigen and plasma levels of sFas and sFasL in patients with aplastic anemia]. Ren C, etal., Zhonghua Xue Ye Xue Za Zhi. 2000 Apr;21(4):198-200.
146. GOA pipeline RGD automated data pipeline
147. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
148. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
149. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Rieux-Laucat F, etal., Science. 1995 Jun 2;268(5215):1347-9.
150. Naringin attenuates liver damage in streptozotocin-induced diabetic rats. Rodríguez V, etal., Biomed Pharmacother. 2018 Sep;105:95-102. doi: 10.1016/j.biopha.2018.05.120. Epub 2018 May 28.
151. IL-6 protects enterocytes from hypoxia-induced apoptosis by induction of bcl-2 mRNA and reduction of fas mRNA. Rollwagen FM, etal., Biochem Biophys Res Commun. 2006 Sep 8;347(4):1094-8. Epub 2006 Jul 13.
152. Fas (CD95/APO-1) plays a role in the pathophysiology of focal cerebral ischemia. Rosenbaum DM, etal., J Neurosci Res. 2000 Sep 15;61(6):686-92.
153. Fas and Fas ligand messenger ribonucleic acid and protein expression in the rat corpus luteum during apoptosis-mediated luteolysis. Roughton SA, etal., Biol Reprod. 1999 Apr;60(4):797-804.
154. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Ryo K, etal., Am J Gastroenterol. 2000 Aug;95(8):2047-55. doi: 10.1111/j.1572-0241.2000.02268.x.
155. Rat liver myofibroblasts and hepatic stellate cells differ in CD95-mediated apoptosis and response to TNF-alpha. Saile B, etal., Am J Physiol Gastrointest Liver Physiol 2002 Aug;283(2):G435-44.
156. 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression. Sako T, etal., In Vivo. 2005 Jan-Feb;19(1):125-32.
157. Cellular expressions and serum concentrations of Fas ligand and Fas receptor in patients with infectious mononucleosis. Sato T, etal., Int J Hematol. 2000 Oct;72(3):329-36.
158. Alternative splicing of the primary Fas transcript generating soluble Fas antagonists is suppressed in the failing human ventricular myocardium. Schumann H, etal., Biochem Biophys Res Commun. 1997 Oct 29;239(3):794-8.
159. Altered expression of Fas receptor on alveolar macrophages and inflammatory effects of soluble Fas ligand following blunt chest trauma. Seitz DH, etal., Shock. 2011 Jun;35(6):610-7. doi: 10.1097/SHK.0b013e318213665d.
160. Fas/FasL mediated apoptosis of thyrocytes in Graves' disease. Sera N, etal., Clin Exp Immunol. 2001 May;124(2):197-207.
161. Intravesicular Fas localization in epithelial cells of castrated rat prostate glands. Serizawa Y, etal., Histol Histopathol. 2001 Apr;16(2):453-62.
162. Prognostic significance of Fas expression in retinoblastoma. Shanmugam MP, etal., Ocul Immunol Inflamm. 2003 Jun;11(2):107-13.
163. Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma. Shen L, etal., Am J Pathol. 2002 Dec;161(6):2123-31.
164. MiR-3202 protects smokers from chronic obstructive pulmonary disease through inhibiting FAIM2: An in vivo and in vitro study. Shen W, etal., Exp Cell Res. 2018 Jan 15;362(2):370-377. doi: 10.1016/j.yexcr.2017.11.038. Epub 2017 Dec 5.
165. p,p'-DDE induces apoptosis and mRNA expression of apoptosis-associated genes in testes of pubertal rats. Shi YQ, etal., Environ Toxicol. 2013 Jan;28(1):31-41. doi: 10.1002/tox.20694. Epub 2011 Mar 7.
166. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Shimonishi T, etal., Hepatology. 2000 Oct;32(4 Pt 1):761-9. doi: 10.1053/jhep.2000.18192.
167. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Sibley K, etal., Cancer Res. 2003 Aug 1;63(15):4327-30.
168. Estrous cycle dependent changes in expression and distribution of Fas, Fas ligand, Bcl-2, Bax, and pro- and active caspase-3 in the rat ovary. Slot KA, etal., J Endocrinol. 2006 Feb;188(2):179-92.
169. Small interference RNA against PTP-1B reduces hypoxia/reoxygenation induced apoptosis of rat cardiomyocytes. Song H, etal., Apoptosis. 2008 Mar;13(3):383-93. doi: 10.1007/s10495-008-0181-1.
170. Stromal Cell-Derived Factor-1a Alleviates Calcium-Sensing Receptor Activation-Mediated Ischemia/Reperfusion Injury by Inhibiting Caspase-3/Caspase-9-Induced Cell Apoptosis in Rat Free Flaps. Song L, etal., Biomed Res Int. 2018 Jan 11;2018:8945850. doi: 10.1155/2018/8945850. eCollection 2018.
171. The many roles of FAS receptor signaling in the immune system. Strasser A, etal., Immunity. 2009 Feb 20;30(2):180-92.
172. Anti-CD95 (APO-1/Fas) autoantibodies and T cell depletion in human immunodeficiency virus type 1 (HIV-1)-infected children. Stricker K, etal., Cell Death Differ. 1998 Mar;5(3):222-30.
173. FasL-Fas interactions regulate neovascularization in the cornea. Stuart PM, etal., Invest Ophthalmol Vis Sci. 2003 Jan;44(1):93-8.
174. Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death. Su JH, etal., Neurobiol Dis. 2003 Apr;12(3):182-93.
175. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Svatek RS, etal., Cancer. 2006 Apr 15;106(8):1701-7.
176. An A > G polymorphism at position -670 in the Fas (TNFRSF6) gene in pregnant women with pre-eclampsia and intrauterine growth restriction. Sziller I, etal., Mol Hum Reprod. 2005 Mar;11(3):207-10. Epub 2005 Feb 4.
177. Analysis of Fas gene mutations on laser capture microdissected specimens from renal cell carcinoma. Takayama H, etal., Jpn J Cancer Res. 2002 Nov;93(11):1201-6.
178. Increased expression of Fas (CD95/APO-1) in adult rat brain after kainate-induced seizures. Tan Z, etal., Neuroreport. 2001 Jul 3;12(9):1979-82.
179. The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. Tsai NM, etal., J Neurochem. 2006 Nov;99(4):1251-62. Epub 2006 Sep 20.
180. Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer. Tseng-Rogenski SS, etal., Cancer Immunol Immunother. 2008 Feb 12;.
181. Intranasal delivery of a Fas-blocking peptide attenuates Fas-mediated apoptosis in brain ischemia. Ullah I, etal., Sci Rep. 2018 Oct 9;8(1):15041. doi: 10.1038/s41598-018-33296-z.
182. Ursodeoxycholyl Lysophosphatidylethanolamide Protects Against CD95/FAS-Induced Fulminant Hepatitis. Utaipan T, etal., Shock. 2017 Aug;48(2):251-259. doi: 10.1097/SHK.0000000000000831.
183. The FAS-670 polymorphism influences susceptibility to multiple sclerosis. van Veen T, etal., J Neuroimmunol. 2002 Jul;128(1-2):95-100.
184. Apoptosis in the kidneys of patients with type II diabetic nephropathy. Verzola D, etal., Kidney Int. 2007 Nov;72(10):1262-72. Epub 2007 Sep 12.
185. Increased expression of apoptosis-associated proteins in puromycin aminonucleoside nephrosis. Viera NT, etal., Invest Clin. 2005 Sep;46(3):273-87.
186. N-Acetyl-l-Cysteine treatment efficiently prevented pre-diabetes and inflamed-dysmetabolic liver development in hypothalamic obese rats. Villagarcía HG, etal., Life Sci. 2018 Apr 15;199:88-95. doi: 10.1016/j.lfs.2018.03.008. Epub 2018 Mar 6.
187. Pressure and endothelial coculture upregulate myocytic Fas-FasL pathway and induce apoptosis by way of direct and paracrine mechanisms. Vouyouka AG, etal., Am J Surg. 2005 Nov;190(5):780-6.
188. c-Jun N-terminal kinases mediate Fas-induced neurite regeneration in PC12 cells. Waetzig V, etal., Biochem Pharmacol. 2008 Dec 1;76(11):1476-84. Epub 2008 Jul 19.
189. Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis. Wahlsten JL, etal., J Immunol. 2000 Nov 15;165(10):5480-6.
190. [Study on expression of Fas/FasL and HBV antigens in liver tissue of patients with hepatitis B]. Wang H, etal., Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2001 Mar;15(1):12-5.
191. Chondrocyte apoptosis and expression of Bcl-2, Bax, Fas, and iNOS in articular cartilage in patients with Kashin-Beck disease. Wang SJ, etal., J Rheumatol. 2006 Mar;33(3):615-9.
192. (-)-Epigallocatechin-3-Gallate Ameliorates Atherosclerosis and Modulates Hepatic Lipid Metabolic Gene Expression in Apolipoprotein E Knockout Mice: Involvement of TTC39B. Wang W, etal., Front Pharmacol. 2018 Mar 9;9:195. doi: 10.3389/fphar.2018.00195. eCollection 2018.
193. Estrogen aggravates iodoacetate-induced temporomandibular joint osteoarthritis. Wang XD, etal., J Dent Res. 2013 Oct;92(10):918-24. doi: 10.1177/0022034513501323. Epub 2013 Aug 9.
194. Insulin-like growth factor-1 treatment prevents anti-Fas antibody-induced apoptosis in endplate chondrocytes. Wang YJ, etal., Spine (Phila Pa 1976). 2006 Apr 1;31(7):736-41.
195. Effect of Huwentoxin-I on the Fas and TNF apoptosis pathway in the hippocampus of rat with global cerebral ischemia. Wang YR, etal., Toxicon. 2007 Dec 15;50(8):1085-94. Epub 2007 Aug 7.
196. Testicular developmental impairment caused by flutamide-induced and DEHP-induced cryptorchid rat models is mediated by excessive apoptosis and deficient autophagy. Wei Y, etal., Toxicol Mech Methods. 2018 Sep;28(7):507-519. doi: 10.1080/15376516.2018.1459994. Epub 2018 Jun 5.
197. [Expression of Fas antigen and Fas ligand in acute liver injury induced by carbon tetrachloride in rat]. Wen T, etal., Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006 Jul;18(7):417-20.
198. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. Wigginton JM, etal., J Clin Invest. 2001 Jul;108(1):51-62.
199. The cardiac Fas (APO-1/CD95) Receptor/Fas ligand system : relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes. Wollert KC, etal., Circulation. 2000 Mar 14;101(10):1172-8.
200. Antagonistic effects of nobiletin, a polymethoxyflavonoid, on eosinophilic airway inflammation of asthmatic rats and relevant mechanisms. Wu YQ, etal., Life Sci. 2006 May 1;78(23):2689-96. Epub 2005 Dec 9.
201. Shedding of Fas ectodomain that affects apoptosis of hepatocytes occurring in regenerative liver. Xia M, etal., J Gastroenterol. 2002;37(12):1042-7.
202. XZ-1 regulates cell apoptosis of gastric epithelial dysplasia via NF-¿B/p53/Ki67 signaling pathway. Xu B, etal., Biosci Rep. 2018 Jun 12;38(3). pii: BSR20171529. doi: 10.1042/BSR20171529. Print 2018 Jun 29.
203. Wei sheng yan jiu = Journal of hygiene research Xu J, etal., Wei Sheng Yan Jiu. 2007 Jul;36(4):443-5.
204. [Experimental study on fas expression of spermatogenic cell in male rats induced by fluorine]. Xu R, etal., Wei Sheng Yan Jiu. 2010 May;39(3):358-60.
205. Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner. Xu W, etal., Toxicol Appl Pharmacol. 2017 Jan 15;315:23-34. doi: 10.1016/j.taap.2016.12.001. Epub 2016 Dec 6.
206. Fas- and FasL-deficient mice are resistant to the induction of bleomycin-induced scleroderma. Yamamoto T, etal., Arch Dermatol Res. 2007 Feb;298(9):465-8. Epub 2006 Nov 11.
207. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Yamana K, etal., Br J Cancer. 2005 Sep 5;93(5):544-51.
208. Shenfu Formula reduces cardiomyocyte apoptosis in heart failure rats by regulating microRNAs. Yan X, etal., J Ethnopharmacol. 2018 May 8;227:105-112. doi: 10.1016/j.jep.2018.05.006.
209. Wentong decoction cures allergic bronchial asthma by regulating the apoptosis imbalance of EOS. Yan Y, etal., Chin Med. 2018 Apr 18;13:21. doi: 10.1186/s13020-018-0180-2. eCollection 2018.
210. Downregulation of IFN-gammaR in association with loss of Fas function is linked to tumor progression. Yang D, etal., Int J Cancer. 2008 Jan 15;122(2):350-62.
211. Effects of Periostracum Cicadae on Cytokines and Apoptosis Regulatory Proteins in an IgA Nephropathy Rat Model. Yang L, etal., Int J Mol Sci. 2018 May 29;19(6). pii: ijms19061599. doi: 10.3390/ijms19061599.
212. Hydrogen peroxide predisposes neonatal rat ventricular myocytes to Fas-mediated apoptosis. Yaniv G, etal., Biochem Biophys Res Commun. 2005 Oct 28;336(3):740-6. doi: 10.1016/j.bbrc.2005.08.167.
213. Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the Fas (CD95/Apo-1) receptor: Fas activation and apoptosis in hypoxic myocytes. Yaniv G, etal., Cardiovasc Res. 2002 Jun;54(3):611-23.
214. Titanium dioxide induces apoptotic cell death through reactive oxygen species-mediated Fas upregulation and Bax activation. Yoo KC, etal., Int J Nanomedicine. 2012;7:1203-14. doi: 10.2147/IJN.S28647. Epub 2012 Mar 5.
215. Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura. Yoshimura C, etal., Eur J Haematol. 2000 Apr;64(4):219-24.
216. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus. Younes M, etal., Hum Pathol. 2000 Apr;31(4):434-8.
217. Human neuropathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy. Yu WR, etal., Brain. 2011 May;134(Pt 5):1277-92. doi: 10.1093/brain/awr054. Epub 2011 Apr 13.
218. Necrosis and apoptosis of renal tubular epithelial cells in rats exposed to 3-methyl-4-nitrophenol. Yue Z, etal., Environ Toxicol. 2012 Nov;27(11):653-61. doi: 10.1002/tox.20688. Epub 2011 Mar 3.
219. Role of the Fas-signaling pathway in photoreceptor neuroprotection. Zacks DN, etal., Arch Ophthalmol. 2007 Oct;125(10):1389-95.
220. FAS-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment. Zacks DN, etal., Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4563-9.
221. The expressions of Fas and caspase-3 in human glaucomatous optic nerve axons. Zalewska R, etal., Med Sci Monit. 2008 Dec;14(12):BR274-8.
222. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Zhang B, etal., Carcinogenesis. 2007 May;28(5):1067-73. Epub 2006 Dec 20.
223. Herb-partitioned moxibustion alleviates colon injuries in ulcerative colitis rats. Zhang D, etal., World J Gastroenterol. 2018 Aug 14;24(30):3384-3397. doi: 10.3748/wjg.v24.i30.3384.
224. The effects of interleukin-10 on the expression of Fas and FasL in rat hepatic stellate cells. Zhang L, etal., Med Chem. 2006 Nov;2(6):611-6.
225. Effects of interleukin-10 on activation and apoptosis of hepatic stellate cells in fibrotic rat liver. Zhang LJ, etal., World J Gastroenterol. 2006 Mar 28;12(12):1918-23.
226. Fas/FasL-dependent apoptosis of hepatocytes induced in rat and patients with Clonorchis sinensis infection. Zhang X, etal., Parasitol Res. 2008 Jul;103(2):393-9. Epub 2008 Apr 22.
227. [Effects of serum anti-sperm antibodies positive on the Fas/Fas-L apoptosis pathway in the testis tissue and testicular germ cells of pubertal male rats]. Zhi EL, etal., Zhonghua Nan Ke Xue. 2013 Feb;19(2):111-5.
228. Accelerated apoptosis contributes to aging-related hyperinflammation in endotoxemia. Zhou M, etal., Int J Mol Med. 2010 Jun;25(6):929-35.
229. Bcl-2 and Fas expression in peripheral blood leukocytes of patients with alcoholic and autoimmune liver disorders. Zwolak A, etal., Hum Exp Toxicol. 2016 Aug;35(8):799-807. doi: 10.1177/0960327115607078. Epub 2015 Oct 1.
Additional References at PubMed
PMID:6610701   PMID:7511063   PMID:7536190   PMID:7538908   PMID:7595210   PMID:7602121   PMID:8524870   PMID:8557033   PMID:8640868   PMID:8666928   PMID:8700551   PMID:8788039  
PMID:9681877   PMID:9697835   PMID:10429671   PMID:10588860   PMID:10950869   PMID:11096076   PMID:11101870   PMID:12011074   PMID:12431371   PMID:12683940   PMID:12702495   PMID:12801066  
PMID:13679421   PMID:14679192   PMID:14699504   PMID:15039234   PMID:15039424   PMID:15254243   PMID:15309723   PMID:15487762   PMID:15632112   PMID:16000635   PMID:16365167   PMID:16493007  
PMID:16507998   PMID:17441510   PMID:17980593   PMID:18199416   PMID:18204739   PMID:18246871   PMID:18289516   PMID:18363966   PMID:18407603   PMID:18614532   PMID:19151726   PMID:19239001  
PMID:19267062   PMID:19399403   PMID:19407976   PMID:19415683   PMID:19593445   PMID:19642903   PMID:20436477   PMID:20448356   PMID:20458337   PMID:20530871   PMID:20935634   PMID:21052097  
PMID:21382479   PMID:21421874   PMID:21586345   PMID:21625644   PMID:21803845   PMID:21868309   PMID:22609371   PMID:22891283   PMID:23583643   PMID:23785138   PMID:23934924   PMID:23973665  
PMID:24307234   PMID:24324791   PMID:24914971   PMID:24938610   PMID:25294749   PMID:25310648   PMID:25439027   PMID:26316710   PMID:27189477   PMID:27561622   PMID:27606894   PMID:27919821  
PMID:28346613   PMID:28595623   PMID:28722192   PMID:29891925   PMID:31155748   PMID:33847039   PMID:33994507  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21231,798,963 - 231,832,591 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1231,798,960 - 231,832,591 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1240,190,049 - 240,223,613 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01247,111,767 - 247,145,407 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01239,949,944 - 239,983,507 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01252,589,785 - 252,624,790 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1252,589,785 - 252,624,790 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01259,812,248 - 259,846,107 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41238,259,443 - 238,274,745 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11238,423,465 - 238,438,767 (+)NCBI
Celera1228,912,823 - 228,946,152 (+)NCBICelera
Cytogenetic Map1q52NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh381088,964,050 - 89,017,059 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1088,953,813 - 89,029,605 (+)EnsemblGRCh38hg38GRCh38
GRCh371090,750,555 - 90,776,816 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361090,740,268 - 90,765,522 (+)NCBINCBI36Build 36hg18NCBI36
Build 341090,740,267 - 90,765,521NCBI
Celera1084,497,075 - 84,522,333 (+)NCBICelera
Cytogenetic Map10q23.31NCBI
HuRef1084,384,755 - 84,410,009 (+)NCBIHuRef
CHM1_11091,032,348 - 91,057,602 (+)NCBICHM1_1
T2T-CHM13v2.01089,847,964 - 89,900,944 (+)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm391934,267,926 - 34,305,175 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1934,268,066 - 34,305,172 (+)EnsemblGRCm39 Ensembl
GRCm381934,290,647 - 34,327,775 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1934,290,666 - 34,327,772 (+)EnsemblGRCm38mm10GRCm38
MGSCv371934,365,149 - 34,402,260 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361934,356,663 - 34,393,767 (+)NCBIMGSCv36mm8
Celera1935,067,780 - 35,104,920 (+)NCBICelera
Cytogenetic Map19C1NCBI
cM Map1929.48NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_0049554253,961,013 - 3,987,455 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049554253,961,671 - 3,987,513 (-)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan110101,002,414 - 101,045,621 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01085,707,457 - 85,741,539 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11089,199,070 - 89,244,884 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1089,217,949 - 89,243,612 (+)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.12638,738,811 - 38,763,298 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl2638,737,611 - 38,763,321 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha2638,489,983 - 38,514,797 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.02640,322,559 - 40,347,441 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl2640,322,604 - 40,347,428 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.12638,193,452 - 38,217,927 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.02637,756,887 - 37,781,708 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.02639,027,502 - 39,052,301 (+)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_02440721378,564,885 - 78,583,646 (+)NCBIHiC_Itri_2
SpeTri2.0NW_004936735209,369 - 234,582 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl14100,927,089 - 100,956,716 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.114100,927,305 - 100,954,781 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.214109,911,730 - 109,939,489 (+)NCBISscrofa10.2Sscrofa10.2susScr3
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_00462479115,289,348 - 15,315,848 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462479115,290,022 - 15,315,848 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Fas
182 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:99
Count of miRNA genes:85
Interacting mature miRNAs:96
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
7794788Mcs32Mammary carcinoma susceptibility QTL 322.61mammary gland integrity trait (VT:0010552)mammary tumor incidence/prevalence measurement (CMO:0000946)1115540693238914717Rat
7421630Bp362Blood pressure QTL 3620.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1118608292241799120Rat
2302378Insul11Insulin level QTL 113.25blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1144267353251128347Rat
724531Uae5Urinary albumin excretion QTL 54urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)1150700142252085212Rat
1578759Uae30Urinary albumin excretion QTL 303.30.003urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1150700247252085048Rat
1578778Pur4Proteinuria QTL 43.30.003urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)1150700247252085048Rat
1354610Bw34Body weight QTL 344.1body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
1354646Kidm18Kidney mass QTL 185.7kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1151162512256448636Rat
1354661Bw33Body weight QTL 335.2body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
1549837Hcar15Hepatocarcinoma resistance QTL 150.05liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1153136852260522016Rat
1354580Scort1Serum corticosterone level QTL 13.4blood corticosterone amount (VT:0005345)blood corticosterone level (CMO:0001172)1156677124256448636Rat
2292220Bp306Blood pressure QTL 3063.470.00087arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1164310393243914901Rat
738032Hcas5Hepatocarcinoma susceptibility QTL 53.12liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1176426412257976495Rat
1354624Cm35Cardiac mass QTL355.7heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1177227632256448636Rat
1354652Kidm20Kidney mass QTL 204.3kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1177227632256448636Rat
634321Hc1Hypercalciuria QTL 12.91urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1178810256240830002Rat
1578763Kidm29Kidney mass QTL 293.30.0001kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)1179567751260522016Rat
8655655Arrd2Age-related retinal degeneration QTL 27.79retinal layer morphology trait (VT:0003727)percentage of study population developing retinopathy during a period of time (CMO:0002453)1183970203243914901Rat
8655855Arrd3Age-related retinal degeneration QTL 33.07lens clarity trait (VT:0001304)cataract incidence/prevalence measurement (CMO:0001585)1183970203243914901Rat
1358898Bp255Blood pressure QTL 2553.6arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1191019702246062233Rat
10059590Kidm44Kidney mass QTL 443.420.025kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1191033875236033875Rat
1358191Ept10Estrogen-induced pituitary tumorigenesis QTL 103.8pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)1192825253243914732Rat
8552891Epfw5Epididymal fat weight QTL 54.4epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)1193113876238113876Rat
1600388Niddm67Non-insulin dependent diabetes mellitus QTL 675.840.000004blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
1600395Niddm69Non-insulin dependent diabetes mellitus QTL 694.140.0002blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1195804352257091168Rat
1600396Niddm68Non-insulin dependent diabetes mellitus QTL 684.970.0003blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
631658Cm7Cardiac mass QTL 75.320.0001aorta mass (VT:0002845)aorta weight (CMO:0000076)1196248093241248093Rat
1358292Cm37Cardiac mass QTL 376.20.00000081heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)1196248093241248093Rat
1600374Mcs17Mammary carcinoma susceptibility QTL 173mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1197670404242670404Rat
1641926Teswt2Testicular weight QTL 22.82testis mass (VT:1000644)both testes wet weight (CMO:0000175)1197697768238755659Rat
2302375Bw83Body weight QTL 834.870.0002body mass (VT:0001259)body weight (CMO:0000012)1197697768242697768Rat
61376Bp42Blood pressure QTL 4223.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1197814409242814409Rat
1298084Thym4Thymus enlargement QTL 410.68thymus mass (VT:0004954)thymus weight to body weight ratio (CMO:0000612)1197814409242814409Rat
1357335Bw39Body weight QTL 393.3body mass (VT:0001259)body weight (CMO:0000012)1197814409242814409Rat
634313Niddm43Non-insulin dependent diabetes mellitus QTL 43blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1199050459259647894Rat
2293694Bss38Bone structure and strength QTL 387.050.0001femur strength trait (VT:0010010)femur stiffness (CMO:0001674)1201554356246554356Rat
7394701Uae46Urinary albumin excretion QTL 463.60.0056urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1201554356246554356Rat
2300175Bmd40Bone mineral density QTL 4015.40.0001femur mineral mass (VT:0010011)bone mineral density (CMO:0001226)1201554356246554356Rat
2293655Bss36Bone structure and strength QTL 3610.660.0001femur strength trait (VT:0010010)femur ultimate force (CMO:0001675)1201554356246554356Rat
2293674Bss39Bone structure and strength QTL 397.10.0001femur strength trait (VT:0010010)femur total energy absorbed before break (CMO:0001677)1201554356246554356Rat
10059587Bw173Body weight QTL 1733.230.025body mass (VT:0001259)body weight (CMO:0000012)1202069611247069611Rat
1600363Hc6Hypercalciuria QTL 62.7urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1203995416244113296Rat
1600397Edcs4Endometrial carcinoma susceptibility QTL 42.2uterus morphology trait (VT:0001120)percentage of study population developing endometrioid carcinoma during a period of time (CMO:0001759)1206081677251081677Rat
1357399Bw45Body weight QTL 453.05body mass (VT:0001259)body mass index (BMI) (CMO:0000105)1206329708251329708Rat
1357404Bw42Body weight QTL 424.490.0001body mass (VT:0001259)body weight (CMO:0000012)1206329708251329708Rat
1358916Kidm22Kidney mass QTL 223.32kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1210702053240947965Rat
1358890Bp259Blood pressure QTL 2593.06arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1210702053260522016Rat
2292216Bw80Body weight QTL 803.230.0019body mass (VT:0001259)body weight (CMO:0000012)1213533809243914901Rat
724538Kidm1Kidney mass QTL 13.2kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1213707201252085212Rat
734768Niddm59Non-insulin dependent diabetes mellitus QTL 59body mass (VT:0001259)body weight (CMO:0000012)1213843987258843987Rat
61455Niddm7Non-insulin dependent diabetes mellitus QTL 75.5blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1214537555238757011Rat
70211Niddm24Non-insulin dependent diabetes mellitus QTL 243.79blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1214647894259647894Rat
1549910Bw54Body weight QTL 540.05body mass (VT:0001259)body weight (CMO:0000012)1214647894259647894Rat
61327Eae7Experimental allergic encephalomyelitis QTL 75.6body mass (VT:0001259)change in body weight (CMO:0002045)1216255568260522016Rat